Tretinoin and arsenic drugs for newly diagnosed acute promyelocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia diagnosis must be confirmed as APL using a specific gene test (PML-RAR-alpha fusion)
- You must be able to read, understand, and sign consent to join a research study
- If you already started urgent APL treatment (ATRA, ATO, and/or one dose of idarubicin), you may still be eligible
- If you can become pregnant, you must have a negative pregnancy blood test at screening and again within 48 hours before starting study drugs
- You must agree to use two reliable birth-control methods during the study if you are sexually active and pregnancy is possible
- Before starting, your heart rhythm test (EKG) must not show a QTcF value above 480 milliseconds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing an oral (pill) form of arsenic trioxide to the standard IV (drip) form. If you have already completed initial therapy for your type of leukemia and are in remission, this study could help you take your medicine as a pill instead of through a needle.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
This trial tests whether adding tretinoin (a form of vitamin A) to the standard combination of azacitidine and venetoclax can help people with newly diagnosed acute myeloid leukemia (AML) who have not yet received treatment. The goal is to see if this triple therapy can improve remission rates and overall outcomes.
Hear when a new Acute Promyelocytic Leukemia With PML-RARA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.